Inhibrx, Inc.·4

May 8, 4:57 PM ET

Deck Kelly 4

4 · Inhibrx, Inc. · Filed May 8, 2024

Insider Transaction Report

Form 4
Period: 2024-05-06
Deck Kelly
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-05-06$34.24/sh17,624$603,4460 total
    Exercise: $10.52Exp: 2028-11-26Common Stock (17,624 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-05-06$34.24/sh2,087$71,4590 total
    Exercise: $11.25Exp: 2030-04-21Common Stock (2,087 underlying)
Footnotes (2)
  • [F1]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
  • [F2]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on April 21, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Documents

1 file
  • 4
    wk-form4_1715201857.xmlPrimary

    FORM 4